Vaxcyte Bolsters Capital Structure with New Offerings
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Vaxcyte (PCVX) closed concurrent equity and convertible debt offerings, raising about $544.3 million from equity and $558.7 million from debt. The deals included $575 million in convertible senior notes plus common stock and pre-funded warrants, giving the biotechnology company greater financial flexibility for strategic and operational initiatives.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.